These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25384936)

  • 1. Commentary on Nolan et al. (2014): Opiate substitution treatment and hepatitis C virus prevention: building an evidence base?
    Vickerman P; Page K; Maher L; Hickman M
    Addiction; 2014 Dec; 109(12):2060-1. PubMed ID: 25384936
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on Cousins et al. (2016): Accumulating evidence on risk of mortality on and off opioid substitution treatment.
    Hickman M; Macleod J; Degenhardt L
    Addiction; 2016 Jan; 111(1):83-4. PubMed ID: 26669528
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary on Burns et al. (2015): retention in buprenorphine treatment.
    Saxon AJ
    Addiction; 2015 Apr; 110(4):656-7. PubMed ID: 25771691
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary on Holland et al. (2014): Opioid maintenance treatment--how much supervision is helpful?
    Koller G
    Addiction; 2014 Apr; 109(4):608-9. PubMed ID: 24605959
    [No Abstract]   [Full Text] [Related]  

  • 5. Methadone and Buprenorphine for Opioid Dependence During Pregnancy: A Retrospective Cohort Study: Re: Meyer et al.
    McCarthy JJ
    J Addict Med; 2016; 10(2):133-4. PubMed ID: 26985649
    [No Abstract]   [Full Text] [Related]  

  • 6. Maintenance medication for opiate addiction: the foundation of recovery.
    Bart G
    J Addict Dis; 2012; 31(3):207-25. PubMed ID: 22873183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 8. Comments on: Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy.
    Jones HE; Heil SH; Kaltenbach K; Stine SM; Coyle MG; Arria AM; O'Grady KE; Selby P; Martin PR
    J Addict Dis; 2012; 31(4):321-6; discussion 327-8. PubMed ID: 23244549
    [No Abstract]   [Full Text] [Related]  

  • 9. Use and misuse of opioid agonists in opioid addiction.
    Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
    Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methadone and buprenorphine during pregnancy.
    Newman RG; Gevertz SG
    J Addict Med; 2015; 9(3):252. PubMed ID: 26020157
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy.
    Newman RG; Gevertz SG
    J Addict Dis; 2011 Oct; 30(4):318-22. PubMed ID: 22026523
    [No Abstract]   [Full Text] [Related]  

  • 12. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
    Kosloski MP; Zhao W; Asatryan A; Kort J; Geoffroy P; Liu W
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28807904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary on Gibson et al. (2020): Medications for opioid use disorder- access, retention, and safety.
    Timko C; Hoggatt K
    Addiction; 2020 Nov; 115(11):2077-2078. PubMed ID: 32458419
    [No Abstract]   [Full Text] [Related]  

  • 15. Commentary on Freelemyer et al. (2014): medication-assisted treatment in Africa-need is growing but response remains tepid.
    Obot IS
    Addiction; 2014 Jan; 109(1):33-4. PubMed ID: 24438111
    [No Abstract]   [Full Text] [Related]  

  • 16. Methadone and buprenorphine treatments in patients with schizophrenia.
    Dervaux A; Plancke L; Amariei A; Trouiller P; Tahon M; Martinetti MP; Naassila M; Cottencin O; Danel T
    Schizophr Res; 2019 Jul; 209():286-288. PubMed ID: 31101511
    [No Abstract]   [Full Text] [Related]  

  • 17. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment.
    Maremmani I; Gerra G
    Am J Addict; 2010; 19(6):557-68. PubMed ID: 20958853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
    Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid agonist treatment for pharmaceutical opioid dependent people.
    Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
    Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.